

CURRICULUM VITAE

LEONARDO M. FABBRI

Professor of Respiratory Medicine and Director

Section of Respiratory Diseases

Department of Oncology, Haematology and Respiratory Diseases

University of Modena and Reggio Emilia

Via del Pozzo 71, 41124 Modena

Phone: (0039-059) 4222198; 4224198;

Fax: (0039-059) 4224231;

Email leonardo.fabbri@unimore.it

Hirsh Index (Harzig's, December 2014): 92

Leonardo M. Fabbri, Professor of Respiratory Medicine; Honorary Professor of Internal Medicine, Director of the Department of Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia; he received doctorate in Medicine and Surgery, University Padua in 1972 (110/110 summa cum laude), Board in Occupational Medicine, University Padua in 1975 (70/70 summa cum laude), Board of Respiratory Medicine, University Bologna in 1978 (70/70 summa cum laude).

Visiting Research Fellow, Department of Respiratory Diseases, Tulane University (1980-1981) and at Cardiovascular Research Institute, University California, San Francisco, USA (1981-1983).

Served as Chief Editor for European Respiratory Review and of the European Respiratory Monograph and as is still Associate Editor of the European Respiratory Journal and of the American Journal of Respiratory and Critical Care Medicine, Lancet Respiratory Medicine, European Journal of Clinical Investigation.

He was member of the Executive Committee of the Global Initiative on Asthma (GINA) (1990–2001); member of Scientific Committee of Global Initiative on Obstructive Lung Disease (GOLD) (1997-2005, and 2009-to date); Chairman of Scientific Committee, GOLD (2001-2004); member of Workshop Panel of GOLD (2001-2005); chairman of Executive Committee GOLD (2004 – 2005), and back again in the Scientific Committee 2009-ta date.

He was President of the European Respiratory Society (ERS) 2007-2008.

He has published > 350 papers in peer reviewed journal plus several book chapters.

Ten selected publications of the last 5 years

1. Papi A, Markus B Beghé B, **and Fabbri LM**; for the AIFASMA Study Group. Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial. Lancet Respir Med 2014 Dec 3. pii: S2213-2600(14)70266-8. doi: 10.1016/S2213-2600(14)70266-8. [Epub ahead of print]

2: Rabe KF, **Fabbri LM**, Israel E, Kögler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med. 2014 Jan;2(1):44-53.

- 3: Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, **Fabbri LM**, Rabe KF. Beclomethasone/formoterol as maintenance and reliever therapy in asthma: A Randomised Controlled Trial. *The Lancet Respiratory Medicine* 2013;1: 23–31.
- 4: Roca M, Verduri A, Corbetta L, Clini E, **Fabbri LM**, Beghé B. Mechanisms of acute exacerbation of respiratory symptoms in COPD. *Eur J Clin Invest* 2013; May;43(5):510-21.
- 5: Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, **Fabbri LM**; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med*. 2011 Mar 24;364(12):1093-1103.
- 6: Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, **Fabbri LM**. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. *J Allergy Clin Immunol*. 2011 Aug;128(2):315-22. PubMed PMID: 21807250
- 7: **Fabbri LM**, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. *Lancet*. 2009 Aug 29;374(9691):695-703. PubMed PMID: 19716961.
- 8: Calverley PM, Rabe KF, Goehring UM, Kristiansen S, **Fabbri LM**, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet*. 2009 Aug 29;374 (9691):685-94. Erratum in: *Lancet*. 2010 Oct 2;376(9747):1146. PubMed PMID: 19716960.
- 9: **Fabbri LM**, Rabe KF. From COPD to chronic systemic inflammatory syndrome? *Lancet*. 2007 Sep 1;370(9589):797-9. PubMed PMID: 17765529.
- 10: Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, and **Fabbri LM**; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. *N Engl J Med*. 2007 May 17;356(20):2040-52. PubMed PMID: 17507703.